CombiMatrix President & CEO, Dr. Amit Kumar, Scheduled to Appear on CNBC Europe.Business Editors/Health/Medical Writers BIOWIRE2K NEWPORT BEACH Newport Beach, residential and resort city (1990 pop. 66,643), Orange co., S Calif., on Newport Bay and the Pacific Ocean; inc. 1906. It is a popular seaside resort and yachting center. Manufactures include electrical and medical equipment, computers, boats, and adhesives. , Calif.--(BUSINESS WIRE)--Oct. 1, 2003 Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ) announced today that Dr. Amit Kumar, President and Chief Executive Officer of CombiMatrix, is scheduled to appear on CNBC Europe CNBC Europe is a business and financial news channel broadcast in Europe. It is the European version of CNBC. It is operated by NBC Universal, and headquartered in London. on Thursday, October 2, 2003 on the Morning Exchange Show at approximately, 10:20 a.m. London time, subject to late breaking news preemptions. ABOUT CNBC EUROPE CNBC Europe is the European cable arm of the US TV network NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. and presents up to the minute market reports, economic and corporate news, analysis on stock movements and market trends, plus interviews with CEO's and politicians and market experts. CNBC Europe broadcasts by cable and satellite in 70 million homes across Europe. www.cnbceurope.com ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies
The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics, drug discovery, and immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. CombiMatrix's Express Track(sm) and siRNA Solutions(tm) are approaches to target diseases with siRNA compounds. The initial focus of Express Track(sm) are the following viral diseases: Virus Collaborator ----- ------------ SARS NIAID/USAMRIID HIV type 1 irsiCaixa-Dr. Bonaventura Clotet HIV type 2 To Be Announced West Nile virus To Be Announced Human Papillomavirus type 16 To Be Announced Human Herpes 8 (Kaposi's sarcoma) To Be Announced Smallpox (Variola) To Be Announced Influenza virus A To Be Announced Influenza virus B To Be Announced Hepatitis C To Be Announced CombiMatrix is also establishing applications of its arrays. These partnerships to expand the use and partnerships include:
Project Collaborator
------- ------------
Cancer Diagnosis (Lymphoma) University of Washington/
Rational Diagnostics
The Acacia Technologies group licenses its DMT See DSL. and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion